 Palm Beach, FL, Aug. 11, 2021 GLOBE NEWSWIRE -- QSAM Biosciences Inc. OTCQB: QSAM, a company developing next generation nuclear medicines, including Samarium-153-DOTMP CycloSam, for the treatment of cancer and related diseases and conditions, announced that the countries of Japan and Canada have granted patents covering high purity therapeutic bone agents in connection with the Companys CycloSam technology. The United States Patent Trademark Office USPTO issued a patent on this innovation last year. 